MDMA


Irwin Naturals Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics

November 30th, 2022 - Ryan Allway

LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced today it reached a binding, arms-length, agreement to acquire Serenity Health, LLC in Louisville, Kentucky, on November 25, 2022. The move continues Irwin’s national ketamine clinic rollup strategy that has seen the Company move quickly toward its […]

harmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

November 2nd, 2022 - Ryan Allway

ALA-002 is PharmAla’s lead drug candidate, showing exceptional safety and efficacy in preclinical rodent models   VANCOUVER, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) — PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug Administration (USFDA) in advance of its pre-IND meeting […]

PharmAla Biotech to supply University of Sydney Clinical Trial with LaNeo™️ MDMA

August 31st, 2022 - Ryan Allway

Second major clinical trial to select PharmAla Biotech as supplier since PharmAla become the first public company to manufacture GMP MDMA   VANCOUVER, August 31, 2022 (Canada Newswire) – PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the University of Sydney’s upcoming Phase 2 Clinical Trial. Founded in 1850, […]

PharmAla Biotech Becomes First Publicly Traded Company to Produce GMP MDMA

August 17th, 2022 - Ryan Allway

PharmAla’s GMP LaNeo MDMA has completed all release testing, is ready for export VANCOUVER, August 17, 2022 (Canada Newswire) – PharmAla Biotech (CSE:MDMA) (the ‘Company’) has achieved a historic milestone: it is currently the only publicly-traded company to have produced GMP MDMA at scale. The company believes that it is currently the only source for […]

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

August 16th, 2022 - Ryan Allway

CEO says licensing amendment positions Optimi to be a “global leader in the safe supply of EU-GMP Psilocybin, MDMA, and other psychedelics” VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational […]

PharmAla Biotech named Exclusive MDMA Supplier to InterVivo Solutions

August 5th, 2022 - Ryan Allway

PharmAla to supply InterVivo and its Clients for the purposes of scientific research   VANCOUVER, BC and TORONTO, Aug. 5, 2022 /CNW/ – PharmAla Biotech (CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo™ MDMA and Engineering MDMA to InterVivo Solutions (Toronto), its client […]

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

July 19th, 2022 - Ryan Allway

Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructure   DENVER, July 19, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced […]

PharmAla Biotech Registers Trademark for MDMA

June 24th, 2022 - Ryan Allway

The Company’s clinical-grade GMP MDMA product is now known as “Laneo”   VANCOUVER, June 24, 2022 (Canada Newswire) – PharmAla Biotech (CSE:MDMA) has registered a trademark for its clinical-grade MDMA product, which shall be marketed as Laneo MDMA. PharmAla is currently the only publicly-traded company to have developed a full manufacturing value chain for MDMA. […]

Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics

June 20th, 2022 - Ryan Allway

Company to maximize world-class EU-GMP operations, potentially opening future revenue- generating opportunities  June 20, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”) or the (“Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, has submitted a request with Health Canada for an amendment […]

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

May 19th, 2022 - Ryan Allway

PharmAla to supply SABI Mind’s Healing Centres, subject to Health Canada approval     VANCOUVER, BC, May 19, 2022 /CNW/ – PharmAla Biotech (CSE: MDMA) is pleased to announce that it has signed an agreement with SABI Mind Inc. which will allow for its GMP MDMA to be administered to patients at SABI Mind’s Healing Centres. SABI […]

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

May 10th, 2022 - Ryan Allway

PharmAla’s GMP MDMA will now be available for both international and domestic customers through CCrest’s well-developed distribution infrastructure   VANCOUVER, BC, May 10, 2022 /CNW/ – PharmAla Biotech (CSE: MDMA) is excited to announce that it has signed an agreement with CCrest Laboratories Inc. which will allow for its GMP MDMA to be delivered to customers in Canada and […]

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

April 11th, 2022 - Ryan Allway

PharmAla’s GMP MDMA will accelerate trial work funded by Australia’s premier Psychedelics charity PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for Mind Medicine Australia. Mind Medicine Australia’s order will be available for delivery later this year, for use in an ethics approved healthy persons trial and will be subject […]

Adastra Announces Completed Submission of Controlled Substances Dealer’s License Application

March 25th, 2022 - Ryan Allway

LANGLEY, BC, March 25, 2022 /CNW/ – Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) (“Adastra” or the “Company”) a Health Canada Licensed cannabis company focused on processing, sales, organoleptic testing and analytical testing, is pleased to announce it completed the submission of its application for a Controlled Drugs and Substances Dealer’s License (“Dealer’s License”) on March 23, 2022. […]

PharmAla Biotech adds David Purcell as Director of Sales

March 14th, 2022 - Ryan Allway

Purcell to Accelerate PharmAla’s GMP MDMA Manufacturing and Sales Business VANCOUVER, BC, March 14, 2022 /CNW/ – In order to better serve its clinical trial customers, PharmAla Biotech Holdings Inc. (CSE: MDMA) is pleased to announce the hiring of Mr. David Purcell as Director of Sales. As a seasoned executive with exceptional business development and […]

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

January 18th, 2022 - Ryan Allway

Under Mydecine’s recently announced Special Access Support and Supply Program, the Company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care.   VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) […]

Pharmala Biotech Announces Hiring of Harpreet Kaur as Vice President of Research

November 2nd, 2021 - Ryan Allway

Dr. Kaur to accelerate PharmAla’s pre-IND program Toronto, Canada – PharmAla Biotech today announced the hiring of Dr. Harpreet Kaur as its new Vice President of Research, responsible for completion of the Company’s Pre-IND research into its novel formulations of MDMA. PharmAla has developed a novel formulation of MDMA, with a focus on reducing the […]

Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement For Psychedelic Molecules with OVR Technology

August 4th, 2021 - Ryan Allway

Agreement Provides Ketamine One With First-of-its-Kind VR Scent Capabilities to Generate More Realistic Immersive Experiences and Help Improve Patient Treatment Outcomes   Vancouver, British Columbia, August 4, 2021 / Globe Newswire / – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and […]

UK Psychedelics Co. Awakn Life Sciences Begins Listing On OTC Markets

July 26th, 2021 - Ryan Allway

Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF), a biotech company with clinical operations in the psychedelics space looking at the UK mental health markets, began trading on Monday in the U.S. OTC markets under the symbol “AWKNF.”   The new OTC listing will allow Awakn to reach a wider variety of investors. The company went […]

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

July 24th, 2021 - Ryan Allway

DENVER, July 21, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that the Company has filed a new patent for MDMA-like compounds further expanding its […]

MagicMed: Bringing the Drug Candidate Library Model to Psychedelics

January 20th, 2021 - Ash Stringer

The psychedelics market is often described as “emerging”, “burgeoning”, and other similar words, and while certainly true to a large extent, investors shouldn’t think for a moment this is all new. It’s far from it. There are scores of clinical and preclinical data to leverage, most collected before the Controlled Substance Act was enacted in […]

MagicMed Shortcuts Commercialization Timeline with University Agreement

November 4th, 2020 - Ryan Allway

Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations for certain therapies targeting life-threatening conditions. MagicMed Industries Inc., a developer of licensable psychedelic molecular derivatives, […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading